Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P08514: Variant p.Glu355Lys

Integrin alpha-IIb
Gene: ITGA2B
Feedback?
Variant information Variant position: help 355 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glutamate (E) to Lysine (K) at position 355 (E355K, p.Glu355Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (E) to large size and basic (K) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In GT1; type I; impairs surface expression of alpha-IIb/beta-3. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 355 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1039 The length of the canonical sequence.
Location on the sequence: help HDLLVGAPLYMESRADRKLA E VGRVYLFLQPRGPHALGAPS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         HDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPS

Mouse                         HDLLVGAPLYMESRADRKLAEVGRVYLFLQPKGPQALSTPT

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 32 – 1039 Integrin alpha-IIb
Chain 32 – 887 Integrin alpha-IIb heavy chain
Topological domain 32 – 993 Extracellular
Repeat 306 – 371 FG-GAP 5
Binding site 336 – 336
Beta strand 352 – 355



Literature citations
Novel point mutations in the alphaIIb subunit (Phe289-->Ser, Glu324-->Lys and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese patients.
Ambo H.; Kamata T.; Handa M.; Kawai Y.; Oda A.; Murata M.; Takada Y.; Ikeda Y.;
Br. J. Haematol. 102:829-840(1998)
Cited for: VARIANTS GT1 SER-320; LYS-355 AND PRO-778; Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann's thrombasthenia.
Ruan J.; Peyruchaud O.; Alberio L.; Valles G.; Clemetson K.; Bourre F.; Nurden A.T.;
Br. J. Haematol. 102:918-925(1998)
Cited for: VARIANTS GT1 LYS-355 AND THR-596;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.